CA2862544A1 - Sample collection devices with blood stabilizing agents - Google Patents
Sample collection devices with blood stabilizing agents Download PDFInfo
- Publication number
- CA2862544A1 CA2862544A1 CA2862544A CA2862544A CA2862544A1 CA 2862544 A1 CA2862544 A1 CA 2862544A1 CA 2862544 A CA2862544 A CA 2862544A CA 2862544 A CA2862544 A CA 2862544A CA 2862544 A1 CA2862544 A1 CA 2862544A1
- Authority
- CA
- Canada
- Prior art keywords
- inhibitor
- blood
- plasma
- agent
- anticoagulant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 114
- 239000008280 blood Substances 0.000 title claims abstract description 114
- 239000003381 stabilizer Substances 0.000 title description 4
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 43
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 37
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 37
- 229940127218 antiplatelet drug Drugs 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 18
- 230000007928 solubilization Effects 0.000 claims abstract description 16
- 238000005063 solubilization Methods 0.000 claims abstract description 16
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 78
- 229960002240 iloprost Drugs 0.000 claims description 63
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 claims description 63
- 239000003112 inhibitor Substances 0.000 claims description 55
- 210000002381 plasma Anatomy 0.000 claims description 49
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 22
- 229920000858 Cyclodextrin Polymers 0.000 claims description 16
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 15
- 102000012479 Serine Proteases Human genes 0.000 claims description 14
- 108010022999 Serine Proteases Proteins 0.000 claims description 14
- 239000000090 biomarker Substances 0.000 claims description 14
- 150000003180 prostaglandins Chemical class 0.000 claims description 14
- 102000035195 Peptidases Human genes 0.000 claims description 13
- 108091005804 Peptidases Proteins 0.000 claims description 13
- 238000003860 storage Methods 0.000 claims description 13
- 102000018389 Exopeptidases Human genes 0.000 claims description 12
- 108010091443 Exopeptidases Proteins 0.000 claims description 12
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 claims description 11
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 239000004365 Protease Substances 0.000 claims description 10
- 229960001123 epoprostenol Drugs 0.000 claims description 10
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 10
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 8
- 229940001468 citrate Drugs 0.000 claims description 8
- 239000002329 esterase inhibitor Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 claims description 7
- 229940122601 Esterase inhibitor Drugs 0.000 claims description 7
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims description 7
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 7
- 102000005927 Cysteine Proteases Human genes 0.000 claims description 6
- 108010005843 Cysteine Proteases Proteins 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 239000004033 plastic Substances 0.000 claims description 6
- 229920003023 plastic Polymers 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 6
- 238000004820 blood count Methods 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 4
- 229940098773 bovine serum albumin Drugs 0.000 claims description 4
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 4
- 229960002768 dipyridamole Drugs 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003001 serine protease inhibitor Substances 0.000 claims description 4
- ZLJOKYGJNOQXDP-OZUBPDBUSA-N 3-[(z)-[(3ar,4r,5r,6as)-4-[(e,3s)-3-cyclohexyl-3-hydroxyprop-1-enyl]-5-hydroxy-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]methyl]benzoic acid Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@H]1C1)/C=C/[C@@H](O)C2CCCCC2)\C1=C/C1=CC=CC(C(O)=O)=C1 ZLJOKYGJNOQXDP-OZUBPDBUSA-N 0.000 claims description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 3
- 229940097362 cyclodextrins Drugs 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 3
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 229950002177 taprostene Drugs 0.000 claims description 3
- 229960000278 theophylline Drugs 0.000 claims description 3
- LGIPMFCHTFFLFR-PRYZLTTQSA-N 13,14-dehydro-15-cyclohexyl Carbaprostacyclin Chemical compound C([C@@H]1[C@H]2CC(/C[C@H]2C[C@H]1O)=C/CCCC(O)=O)#CC1(O)CCCCC1 LGIPMFCHTFFLFR-PRYZLTTQSA-N 0.000 claims description 2
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 claims description 2
- RJADQDXZYFCVHV-JQMWNLLFSA-N 5-[(2s,4r,5r,6ar)-5-hydroxy-4-[(e,3s)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]furan-2-yl]pentanoic acid Chemical compound O1[C@@H](CCCCC(O)=O)CC2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@H]21 RJADQDXZYFCVHV-JQMWNLLFSA-N 0.000 claims description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 2
- XZFRIPGNUQRGPI-WBQKLGIQSA-N Carbaprostacyclin Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 XZFRIPGNUQRGPI-WBQKLGIQSA-N 0.000 claims description 2
- VKPYUUBEDXIQIB-QBPWRKFFSA-N Ciprostene Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@]21C VKPYUUBEDXIQIB-QBPWRKFFSA-N 0.000 claims description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims description 2
- 101710090406 Meprin A subunit alpha Proteins 0.000 claims description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 2
- 229940122055 Serine protease inhibitor Drugs 0.000 claims description 2
- 101710102218 Serine protease inhibitor Proteins 0.000 claims description 2
- 229960005305 adenosine Drugs 0.000 claims description 2
- 229960002890 beraprost Drugs 0.000 claims description 2
- CTPOHARTNNSRSR-APJZLKAGSA-N beraprost Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-APJZLKAGSA-N 0.000 claims description 2
- 229950009522 ciprostene Drugs 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 229960001259 diclofenac Drugs 0.000 claims description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 2
- 229960002986 dinoprostone Drugs 0.000 claims description 2
- QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical group [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 229960001680 ibuprofen Drugs 0.000 claims description 2
- 229960000905 indomethacin Drugs 0.000 claims description 2
- OJZYRQPMEIEQFC-UAWLTFRCSA-N limaprost Chemical compound CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O OJZYRQPMEIEQFC-UAWLTFRCSA-N 0.000 claims description 2
- 229950009365 limaprost Drugs 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 229960001929 meloxicam Drugs 0.000 claims description 2
- 229960003574 milrinone Drugs 0.000 claims description 2
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 claims description 2
- 229960002009 naproxen Drugs 0.000 claims description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 2
- 150000003891 oxalate salts Chemical class 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 229960002702 piroxicam Drugs 0.000 claims description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 2
- 235000019833 protease Nutrition 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
- 229960003676 tenidap Drugs 0.000 claims description 2
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 claims description 2
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 claims description 2
- 229960002871 tenoxicam Drugs 0.000 claims description 2
- 230000009974 thixotropic effect Effects 0.000 claims description 2
- REZGGXNDEMKIQB-UHFFFAOYSA-N zaprinast Chemical compound CCCOC1=CC=CC=C1C1=NC(=O)C2=NNNC2=N1 REZGGXNDEMKIQB-UHFFFAOYSA-N 0.000 claims description 2
- 229950005371 zaprinast Drugs 0.000 claims description 2
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 claims 3
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 claims 1
- 229960000711 alprostadil Drugs 0.000 claims 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims 1
- 235000019419 proteases Nutrition 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 abstract description 27
- 238000011105 stabilization Methods 0.000 abstract description 27
- 239000003814 drug Substances 0.000 abstract description 7
- 210000001772 blood platelet Anatomy 0.000 description 64
- 102100023472 P-selectin Human genes 0.000 description 35
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 32
- 239000000523 sample Substances 0.000 description 22
- -1 polyethylene Polymers 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 15
- 230000010118 platelet activation Effects 0.000 description 15
- 239000008187 granular material Substances 0.000 description 14
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 14
- 102100033639 Acetylcholinesterase Human genes 0.000 description 11
- 108010022752 Acetylcholinesterase Proteins 0.000 description 11
- 102100025222 CD63 antigen Human genes 0.000 description 11
- 108010055166 Chemokine CCL5 Proteins 0.000 description 11
- 102000001327 Chemokine CCL5 Human genes 0.000 description 11
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 10
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 10
- 229940022698 acetylcholinesterase Drugs 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 101150057744 PDGFA gene Proteins 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 108090001007 Interleukin-8 Proteins 0.000 description 8
- 102000004890 Interleukin-8 Human genes 0.000 description 8
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 239000000654 additive Substances 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 8
- 229960001685 tacrine Drugs 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000011859 microparticle Substances 0.000 description 7
- 210000004623 platelet-rich plasma Anatomy 0.000 description 7
- FHZSIZRTNHGLSX-FLMSMKGQSA-N (2s)-1-[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carboxyl Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=CC=C1 FHZSIZRTNHGLSX-FLMSMKGQSA-N 0.000 description 6
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 6
- 102000003790 Thrombin receptors Human genes 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000018127 platelet degranulation Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 108010093640 thrombin receptor peptide SFLLRNP Proteins 0.000 description 6
- 229940124596 AChE inhibitor Drugs 0.000 description 5
- 102100032404 Cholinesterase Human genes 0.000 description 5
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 239000010836 blood and blood product Substances 0.000 description 5
- 229940125691 blood product Drugs 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 5
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 108010016626 Dipeptides Proteins 0.000 description 4
- 108090000371 Esterases Proteins 0.000 description 4
- 239000001116 FEMA 4028 Substances 0.000 description 4
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 229960004853 betadex Drugs 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- YSJSSHIVMXYVNW-ZVWHLABXSA-N chembl1684446 Chemical compound Cl.N1=C2C=C(Cl)C=CC2=C(N)C2=C1C[C@H]1C=C(CC)C[C@@H]2C1 YSJSSHIVMXYVNW-ZVWHLABXSA-N 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- KETQAJRQOHHATG-UHFFFAOYSA-N 1,2-naphthoquinone Chemical compound C1=CC=C2C(=O)C(=O)C=CC2=C1 KETQAJRQOHHATG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 3
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 3
- 108010053652 Butyrylcholinesterase Proteins 0.000 description 3
- 108010051152 Carboxylesterase Proteins 0.000 description 3
- 102000013392 Carboxylesterase Human genes 0.000 description 3
- 102100021587 Embryonic testis differentiation protein homolog A Human genes 0.000 description 3
- 101000898120 Homo sapiens Embryonic testis differentiation protein homolog A Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000005741 Metalloproteases Human genes 0.000 description 3
- 108010006035 Metalloproteases Proteins 0.000 description 3
- 108010035766 P-Selectin Proteins 0.000 description 3
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 3
- ITZOKHKOFJOBFS-UHFFFAOYSA-N bis(7)-tacrine Chemical compound C1=CC=C2C(NCCCCCCCNC=3C4=CC=CC=C4N=C4CCCCC4=3)=C(CCCC3)C3=NC2=C1 ITZOKHKOFJOBFS-UHFFFAOYSA-N 0.000 description 3
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000002132 lysosomal effect Effects 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- JFRYPNLJVPMTIS-UHFFFAOYSA-N n'-ethyl-n-(1,2,3,4-tetrahydroacridin-9-yl)-n'-[3-(1,2,3,4-tetrahydroacridin-9-ylamino)propyl]propane-1,3-diamine Chemical compound C1=CC=C2C(NCCCN(CCCNC=3C4=CC=CC=C4N=C4CCCCC4=3)CC)=C(CCCC3)C3=NC2=C1 JFRYPNLJVPMTIS-UHFFFAOYSA-N 0.000 description 3
- IIQODJRESHGVGO-UHFFFAOYSA-N n'-methyl-n-(1,2,3,4-tetrahydroacridin-9-yl)-n'-[3-(1,2,3,4-tetrahydroacridin-9-ylsulfanyl)propyl]propane-1,3-diamine Chemical compound C1=CC=C2C(SCCCN(CCCNC=3C4=CC=CC=C4N=C4CCCCC4=3)C)=C(CCCC3)C3=NC2=C1 IIQODJRESHGVGO-UHFFFAOYSA-N 0.000 description 3
- BCRWNRSCYSXXGB-UHFFFAOYSA-N n'-prop-2-enyl-n-(1,2,3,4-tetrahydroacridin-9-yl)-n'-[3-(1,2,3,4-tetrahydroacridin-9-ylamino)propyl]propane-1,3-diamine Chemical compound C1=CC=C2C(NCCCN(CCCNC=3C4=CC=CC=C4N=C4CCCCC4=3)CC=C)=C(CCCC3)C3=NC2=C1 BCRWNRSCYSXXGB-UHFFFAOYSA-N 0.000 description 3
- QRIQNQYNWBQHLY-UHFFFAOYSA-N n-[7-(1,2,3,4-tetrahydroacridin-9-ylsulfanyl)heptyl]-1,2,3,4-tetrahydroacridin-9-amine Chemical compound C1=CC=C2C(SCCCCCCCNC=3C4=CC=CC=C4N=C4CCCCC4=3)=C(CCCC3)C3=NC2=C1 QRIQNQYNWBQHLY-UHFFFAOYSA-N 0.000 description 3
- LEWUCBWUGAIBAD-UHFFFAOYSA-N n-[8-(1,2,3,4-tetrahydroacridin-9-yl)octyl]-1,2,3,4-tetrahydroacridin-9-amine Chemical compound C1=CC=C2C(NCCCCCCCCC=3C4=CC=CC=C4N=C4CCCCC4=3)=C(CCCC3)C3=NC2=C1 LEWUCBWUGAIBAD-UHFFFAOYSA-N 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- CDOZDBSBBXSXLB-UHFFFAOYSA-N profenamine Chemical compound C1=CC=C2N(CC(C)N(CC)CC)C3=CC=CC=C3SC2=C1 CDOZDBSBBXSXLB-UHFFFAOYSA-N 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000002753 trypsin inhibitor Substances 0.000 description 3
- 229950009811 ubenimex Drugs 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- HAGOWCONESKMDW-FRSCJGFNSA-N (2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CC=CC=C1 HAGOWCONESKMDW-FRSCJGFNSA-N 0.000 description 2
- RHWRWEUCEXUUAV-ZSESPEEFSA-N 2-[[(1r,2r,3as,9as)-2-hydroxy-1-[(3s)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1h-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid;2-(2-hydroxyethylamino)ethanol Chemical compound OCCNCCO.C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 RHWRWEUCEXUUAV-ZSESPEEFSA-N 0.000 description 2
- QDFHIWZDZCQXJR-UHFFFAOYSA-N 2-[bis[3-(1,2,3,4-tetrahydroacridin-9-ylamino)propyl]amino]ethanol Chemical compound C1=CC=C2C(NCCCN(CCCNC=3C4=CC=CC=C4N=C4CCCCC4=3)CCO)=C(CCCC3)C3=NC2=C1 QDFHIWZDZCQXJR-UHFFFAOYSA-N 0.000 description 2
- RSGFPIWWSCWCFJ-VAXZQHAWSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O RSGFPIWWSCWCFJ-VAXZQHAWSA-N 0.000 description 2
- TVJGNZTYBOUSAY-UHFFFAOYSA-N 6,8-dichloro-n-[7-(1,2,3,4-tetrahydroacridin-9-ylsulfanyl)heptyl]-1,2,3,4-tetrahydroacridin-9-amine Chemical compound C1CCCC2=NC3=CC(Cl)=CC(Cl)=C3C(NCCCCCCCSC=3C4=CC=CC=C4N=C4CCCCC4=3)=C21 TVJGNZTYBOUSAY-UHFFFAOYSA-N 0.000 description 2
- IHHSSHCBRVYGJX-UHFFFAOYSA-N 6-chloro-2-methoxyacridin-9-amine Chemical compound C1=C(Cl)C=CC2=C(N)C3=CC(OC)=CC=C3N=C21 IHHSSHCBRVYGJX-UHFFFAOYSA-N 0.000 description 2
- VQEZQHKNDTXZIP-UHFFFAOYSA-N 9-ethylidene-4,4,7-trimethyl-3-N-[7-(1,2,3,4-tetrahydroacridin-9-ylamino)heptyl]bicyclo[3.3.1]non-6-ene-1,3-diamine Chemical compound C1=CC=C2C(NCCCCCCCNC3CC4(N)CC(C)=CC(C3(C)C)C4=CC)=C(CCCC3)C3=NC2=C1 VQEZQHKNDTXZIP-UHFFFAOYSA-N 0.000 description 2
- CNCWLWGSZNPHQK-UHFFFAOYSA-N 9-ethylidene-7-methyl-3-N-[7-(1,2,3,4-tetrahydroacridin-9-ylamino)heptyl]bicyclo[3.3.1]non-6-ene-1,3-diamine Chemical compound C1=CC=C2C(NCCCCCCCNC3CC4C(C(C3)(N)CC(C)=C4)=CC)=C(CCCC3)C3=NC2=C1 CNCWLWGSZNPHQK-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 108010087765 Antipain Proteins 0.000 description 2
- 102000007590 Calpain Human genes 0.000 description 2
- 108010032088 Calpain Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108090000322 Cholinesterases Proteins 0.000 description 2
- 101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 description 2
- 101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- 229940094664 Cysteine protease inhibitor Drugs 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 2
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 2
- 206010065042 Immune reconstitution inflammatory syndrome Diseases 0.000 description 2
- 102100026236 Interleukin-8 Human genes 0.000 description 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229940122344 Peptidase inhibitor Drugs 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- QFAADIRHLBXJJS-ZAZJUGBXSA-N amastatin Chemical compound CC(C)C[C@@H](N)[C@H](O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O QFAADIRHLBXJJS-ZAZJUGBXSA-N 0.000 description 2
- 108010052590 amastatin Proteins 0.000 description 2
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940048961 cholinesterase Drugs 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 2
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- KSCFJBIXMNOVSH-UHFFFAOYSA-N dyphylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)CO)C=N2 KSCFJBIXMNOVSH-UHFFFAOYSA-N 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- CIKWKGFPFXJVGW-UHFFFAOYSA-N ethacridine Chemical compound C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 CIKWKGFPFXJVGW-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 229960003980 galantamine Drugs 0.000 description 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- CATSNJVOTSVZJV-UHFFFAOYSA-N heptan-2-one Chemical compound CCCCCC(C)=O CATSNJVOTSVZJV-UHFFFAOYSA-N 0.000 description 2
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003617 indole-3-acetic acid Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
- 108010052968 leupeptin Proteins 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- GXLCMIZDIFTAHJ-UHFFFAOYSA-N methyl 9-ethylidene-3-methyl-7-[7-(1,2,3,4-tetrahydroacridin-9-ylamino)heptylamino]bicyclo[3.3.1]non-3-ene-1-carboxylate Chemical compound C1=CC=C2C(NCCCCCCCNC3CC4(CC(C)=CC(C3)C4=CC)C(=O)OC)=C(CCCC3)C3=NC2=C1 GXLCMIZDIFTAHJ-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- DYTNXFSVOOZIHV-UHFFFAOYSA-N n'-methyl-n-(1,2,3,4-tetrahydroacridin-9-yl)-n'-[3-(1,2,3,4-tetrahydroacridin-9-ylamino)propyl]propane-1,3-diamine Chemical compound C1=CC=C2C(NCCCN(CCCNC=3C4=CC=CC=C4N=C4CCCCC4=3)C)=C(CCCC3)C3=NC2=C1 DYTNXFSVOOZIHV-UHFFFAOYSA-N 0.000 description 2
- ZIDVXYDWJIVBSC-UHFFFAOYSA-N n,n'-bis(1,2,3,4-tetrahydroacridin-9-yl)octane-1,8-diamine Chemical compound C1=CC=C2C(NCCCCCCCCNC=3C4=CC=CC=C4N=C4CCCCC4=3)=C(CCCC3)C3=NC2=C1 ZIDVXYDWJIVBSC-UHFFFAOYSA-N 0.000 description 2
- NECDJQNRWSICKG-UHFFFAOYSA-N n,n'-bis(1,2,3,4-tetrahydroacridin-9-yl)pentane-1,5-diamine Chemical compound C1=CC=C2C(NCCCCCNC=3C4=CC=CC=C4N=C4CCCCC4=3)=C(CCCC3)C3=NC2=C1 NECDJQNRWSICKG-UHFFFAOYSA-N 0.000 description 2
- TWECJTVNEQDUIG-UHFFFAOYSA-N n-[3-(1,2,3,4-tetrahydroacridin-9-ylamino)propyl]-n-[3-(1,2,3,4-tetrahydroacridin-9-ylsulfanyl)propyl]acetamide Chemical compound C1=CC=C2C(SCCCN(CCCNC=3C4=CC=CC=C4N=C4CCCCC4=3)C(=O)C)=C(CCCC3)C3=NC2=C1 TWECJTVNEQDUIG-UHFFFAOYSA-N 0.000 description 2
- WMLGPNPGGGQPET-UHFFFAOYSA-N n-[3-(1,2,3,4-tetrahydroacridin-9-ylamino)propyl]-n-[4-(1,2,3,4-tetrahydroacridin-9-ylsulfanyl)butyl]acetamide Chemical compound C1=CC=C2C(NCCCN(CCCCSC=3C4=CC=CC=C4N=C4CCCCC4=3)C(=O)C)=C(CCCC3)C3=NC2=C1 WMLGPNPGGGQPET-UHFFFAOYSA-N 0.000 description 2
- IADLMALHTDAHCP-UHFFFAOYSA-N n-[6-(1,2,3,4-tetrahydroacridin-9-ylsulfanyl)hexyl]-1,2,3,4-tetrahydroacridin-9-amine Chemical compound C1=CC=C2C(NCCCCCCSC=3C4=CC=CC=C4N=C4CCCCC4=3)=C(CCCC3)C3=NC2=C1 IADLMALHTDAHCP-UHFFFAOYSA-N 0.000 description 2
- COEYCPFFRLYNSC-UHFFFAOYSA-N n-[8-(1,2,3,4-tetrahydroacridin-9-ylsulfanyl)octyl]-1,2,3,4-tetrahydroacridin-9-amine Chemical compound C1=CC=C2C(NCCCCCCCCSC=3C4=CC=CC=C4N=C4CCCCC4=3)=C(CCCC3)C3=NC2=C1 COEYCPFFRLYNSC-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 229950000964 pepstatin Drugs 0.000 description 2
- 108010091212 pepstatin Proteins 0.000 description 2
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229960002262 profenamine Drugs 0.000 description 2
- 150000003815 prostacyclins Chemical class 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 239000005060 rubber Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940032712 succinylcholine Drugs 0.000 description 2
- AXOIZCJOOAYSMI-UHFFFAOYSA-N succinylcholine Chemical compound C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C AXOIZCJOOAYSMI-UHFFFAOYSA-N 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 108010063955 thrombin receptor peptide (42-47) Proteins 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- ZRJBHWIHUMBLCN-MEBBXXQBSA-N (-)-Huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-MEBBXXQBSA-N 0.000 description 1
- JNTMAZFVYNDPLB-PEDHHIEDSA-N (2S,3S)-2-[[[(2S)-1-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JNTMAZFVYNDPLB-PEDHHIEDSA-N 0.000 description 1
- MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
- IJWCGVPEDDQUDE-YGJAXBLXSA-N (2s)-2-[[(1s)-2-[[(2s)-5-amino-1,5-dioxo-1-[[(2s)-1-oxopropan-2-yl]amino]pentan-2-yl]amino]-1-[(6s)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-2-oxoethyl]carbamoylamino]-4-methylpentanoic acid Chemical compound O=C[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H]1CCN=C(N)N1 IJWCGVPEDDQUDE-YGJAXBLXSA-N 0.000 description 1
- TZJGKUCHNFFHGN-LURJTMIESA-N (2s)-2-aminohexanal Chemical compound CCCC[C@H](N)C=O TZJGKUCHNFFHGN-LURJTMIESA-N 0.000 description 1
- PMHUSCHKTSTQEP-UHFFFAOYSA-N (4-carbamimidoylphenyl)methanesulfonyl fluoride Chemical compound NC(=N)C1=CC=C(CS(F)(=O)=O)C=C1 PMHUSCHKTSTQEP-UHFFFAOYSA-N 0.000 description 1
- 229940105324 1,2-naphthoquinone Drugs 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- DEQUVVKHJCRELI-UHFFFAOYSA-N 1-methyl-3-(2-methylpropyl)-7h-purine-2,6-dione;1,3,7-trimethylpurine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C.O=C1N(C)C(=O)N(CC(C)C)C2=C1NC=N2 DEQUVVKHJCRELI-UHFFFAOYSA-N 0.000 description 1
- HLCPWBZNUKCSBN-UHFFFAOYSA-N 2-aminobenzonitrile Chemical compound NC1=CC=CC=C1C#N HLCPWBZNUKCSBN-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- ISIFYDUQYVDLRB-UHFFFAOYSA-N 3,4-dihydroacridin-9-amine Chemical compound C1=CC=C2C(N)=C(C=CCC3)C3=NC2=C1 ISIFYDUQYVDLRB-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- IHTWXNNXMUDSJE-UHFFFAOYSA-N 4-chloro-2-[(3-oxocyclohexen-1-yl)amino]benzonitrile Chemical compound ClC1=CC=C(C#N)C(NC=2CCCC(=O)C=2)=C1 IHTWXNNXMUDSJE-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- ISUJWDYWYFLQFP-UHFFFAOYSA-N 6,8-dichloro-1,2,3,4-tetrahydroacridin-9-amine Chemical compound ClC1=CC(Cl)=C2C(N)=C(CCCC3)C3=NC2=C1 ISUJWDYWYFLQFP-UHFFFAOYSA-N 0.000 description 1
- WUNJSFUQRGEAEJ-UHFFFAOYSA-N 6-chloro-9-[(4-fluorophenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC(Cl)=CC=C2C=1NCC1=CC=C(F)C=C1 WUNJSFUQRGEAEJ-UHFFFAOYSA-N 0.000 description 1
- CZLXRIUEMFZWNY-UHFFFAOYSA-N 6-chloro-9-[(4-fluorophenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound C1=CC(F)=CC=C1CNC1=C(C(=O)CCC2)C2=NC2=CC(Cl)=CC=C12 CZLXRIUEMFZWNY-UHFFFAOYSA-N 0.000 description 1
- LSWZHJUDTDSZPN-UHFFFAOYSA-N 6-fluoro-9-[[2-(trifluoromethyl)phenyl]methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC(F)=CC=C2C=1NCC1=CC=CC=C1C(F)(F)F LSWZHJUDTDSZPN-UHFFFAOYSA-N 0.000 description 1
- OZCGCAPFASUXEH-UHFFFAOYSA-N 6-fluoro-9-[[2-(trifluoromethyl)phenyl]methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound C=12C(=O)CCCC2=NC2=CC(F)=CC=C2C=1NCC1=CC=CC=C1C(F)(F)F OZCGCAPFASUXEH-UHFFFAOYSA-N 0.000 description 1
- MXOVYZNOSVDQMC-UHFFFAOYSA-N 7,9-diamino-3,4-dihydro-2h-acridin-1-one Chemical compound C1CCC(=O)C2=C(N)C3=CC(N)=CC=C3N=C21 MXOVYZNOSVDQMC-UHFFFAOYSA-N 0.000 description 1
- CSTQOUIHHVJLQT-UHFFFAOYSA-N 9-(2-phenylethylamino)-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCCC1=CC=CC=C1 CSTQOUIHHVJLQT-UHFFFAOYSA-N 0.000 description 1
- KLCMFEHXVCLFMX-UHFFFAOYSA-N 9-(2-phenylethylamino)-3,4-dihydro-2h-acridin-1-one Chemical compound C=12C(=O)CCCC2=NC2=CC=CC=C2C=1NCCC1=CC=CC=C1 KLCMFEHXVCLFMX-UHFFFAOYSA-N 0.000 description 1
- OMPBZSLBVKDSJL-UHFFFAOYSA-N 9-(3-phenoxypropylamino)-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCCCOC1=CC=CC=C1 OMPBZSLBVKDSJL-UHFFFAOYSA-N 0.000 description 1
- IHSFBFHFFMJLSM-UHFFFAOYSA-N 9-(3-phenoxypropylamino)-3,4-dihydro-2h-acridin-1-one Chemical compound C=12C(=O)CCCC2=NC2=CC=CC=C2C=1NCCCOC1=CC=CC=C1 IHSFBFHFFMJLSM-UHFFFAOYSA-N 0.000 description 1
- BLNORRZQXAGKJT-UHFFFAOYSA-N 9-(4,4-diphenylbutylamino)-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCCCC(C=1C=CC=CC=1)C1=CC=CC=C1 BLNORRZQXAGKJT-UHFFFAOYSA-N 0.000 description 1
- XILLXTVXJMBMSG-UHFFFAOYSA-N 9-(4,4-diphenylbutylamino)-3,4-dihydro-2h-acridin-1-one Chemical compound C=12C(=O)CCCC2=NC2=CC=CC=C2C=1NCCCC(C=1C=CC=CC=1)C1=CC=CC=C1 XILLXTVXJMBMSG-UHFFFAOYSA-N 0.000 description 1
- YJHBLVYLSYRPFV-UHFFFAOYSA-N 9-(4,4-diphenylbutylamino)-6-(trifluoromethyl)-3,4-dihydro-2h-acridin-1-one Chemical compound C=12C(=O)CCCC2=NC2=CC(C(F)(F)F)=CC=C2C=1NCCCC(C=1C=CC=CC=1)C1=CC=CC=C1 YJHBLVYLSYRPFV-UHFFFAOYSA-N 0.000 description 1
- HERUZAOANPGYSY-UHFFFAOYSA-N 9-(benzylamino)-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCC1=CC=CC=C1 HERUZAOANPGYSY-UHFFFAOYSA-N 0.000 description 1
- JMKIIRWHVISOBM-UHFFFAOYSA-N 9-(benzylamino)-3,4-dihydro-2h-acridin-1-one Chemical compound C=12C(=O)CCCC2=NC2=CC=CC=C2C=1NCC1=CC=CC=C1 JMKIIRWHVISOBM-UHFFFAOYSA-N 0.000 description 1
- YKLOVXPOXRDRPU-UHFFFAOYSA-N 9-(benzylamino)-6-(trifluoromethyl)-3,4-dihydro-2h-acridin-1-one Chemical compound C=12C(=O)CCCC2=NC2=CC(C(F)(F)F)=CC=C2C=1NCC1=CC=CC=C1 YKLOVXPOXRDRPU-UHFFFAOYSA-N 0.000 description 1
- UFBJNPUZMUQXFV-UHFFFAOYSA-N 9-(benzylamino)-6-chloro-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC(Cl)=CC=C2C=1NCC1=CC=CC=C1 UFBJNPUZMUQXFV-UHFFFAOYSA-N 0.000 description 1
- LWGKFQQSAQUNMS-UHFFFAOYSA-N 9-(benzylamino)-6-chloro-3,4-dihydro-2h-acridin-1-one Chemical compound C=12C(=O)CCCC2=NC2=CC(Cl)=CC=C2C=1NCC1=CC=CC=C1 LWGKFQQSAQUNMS-UHFFFAOYSA-N 0.000 description 1
- PRBCPEIUILMRLL-UHFFFAOYSA-N 9-(benzylamino)-6-fluoro-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC(F)=CC=C2C=1NCC1=CC=CC=C1 PRBCPEIUILMRLL-UHFFFAOYSA-N 0.000 description 1
- GLEMXKXJZHWCME-UHFFFAOYSA-N 9-(benzylamino)-6-fluoro-3,4-dihydro-2h-acridin-1-one Chemical compound C=12C(=O)CCCC2=NC2=CC(F)=CC=C2C=1NCC1=CC=CC=C1 GLEMXKXJZHWCME-UHFFFAOYSA-N 0.000 description 1
- XDEHAZKZBBCVGR-UHFFFAOYSA-N 9-(benzylamino)-6-methyl-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC(C)=CC=C2C=1NCC1=CC=CC=C1 XDEHAZKZBBCVGR-UHFFFAOYSA-N 0.000 description 1
- PFNNWRPESNOURZ-UHFFFAOYSA-N 9-(benzylamino)-6-methyl-3,4-dihydro-2h-acridin-1-one Chemical compound C=12C(=O)CCCC2=NC2=CC(C)=CC=C2C=1NCC1=CC=CC=C1 PFNNWRPESNOURZ-UHFFFAOYSA-N 0.000 description 1
- WETURUQUTKXZKR-UHFFFAOYSA-N 9-(methylamino)-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C1=CC=C2C(NC)=C(C(O)CCC3)C3=NC2=C1 WETURUQUTKXZKR-UHFFFAOYSA-N 0.000 description 1
- XSVDUOBBVOQJNN-UHFFFAOYSA-N 9-(methylamino)-3,4-dihydro-2h-acridin-1-one Chemical compound C1=CC=C2C(NC)=C(C(=O)CCC3)C3=NC2=C1 XSVDUOBBVOQJNN-UHFFFAOYSA-N 0.000 description 1
- YHPKDQOHCJWZKV-UHFFFAOYSA-N 9-(methylamino)-7-nitro-3,4-dihydro-2h-acridin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(NC)=C(C(=O)CCC3)C3=NC2=C1 YHPKDQOHCJWZKV-UHFFFAOYSA-N 0.000 description 1
- XRKIMANYLDOPAR-UHFFFAOYSA-N 9-(propylamino)-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C1=CC=C2C(NCCC)=C(C(O)CCC3)C3=NC2=C1 XRKIMANYLDOPAR-UHFFFAOYSA-N 0.000 description 1
- BNISHPZXZUTEFE-UHFFFAOYSA-N 9-(propylamino)-3,4-dihydro-2h-acridin-1-one Chemical compound C1=CC=C2C(NCCC)=C(C(=O)CCC3)C3=NC2=C1 BNISHPZXZUTEFE-UHFFFAOYSA-N 0.000 description 1
- HVYUZYLNNWIMHS-UHFFFAOYSA-N 9-(thiophen-2-ylmethylamino)-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCC1=CC=CS1 HVYUZYLNNWIMHS-UHFFFAOYSA-N 0.000 description 1
- OANFKRNIOKICTD-UHFFFAOYSA-N 9-(thiophen-2-ylmethylamino)-3,4-dihydro-2h-acridin-1-one Chemical compound C=12C(=O)CCCC2=NC2=CC=CC=C2C=1NCC1=CC=CS1 OANFKRNIOKICTD-UHFFFAOYSA-N 0.000 description 1
- SHMLXHJDPNXDDR-UHFFFAOYSA-N 9-[(2,3,4,5,6-pentafluorophenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCC1=C(F)C(F)=C(F)C(F)=C1F SHMLXHJDPNXDDR-UHFFFAOYSA-N 0.000 description 1
- FSLRERHYHIHAKK-UHFFFAOYSA-N 9-[(2,3,4,5,6-pentafluorophenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1CNC1=C(C(=O)CCC2)C2=NC2=CC=CC=C12 FSLRERHYHIHAKK-UHFFFAOYSA-N 0.000 description 1
- XFWKEFHMUGMJLM-UHFFFAOYSA-N 9-[(2-chlorophenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCC1=CC=CC=C1Cl XFWKEFHMUGMJLM-UHFFFAOYSA-N 0.000 description 1
- BEQRYHCXYAFPRU-UHFFFAOYSA-N 9-[(2-chlorophenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound ClC1=CC=CC=C1CNC1=C(C(=O)CCC2)C2=NC2=CC=CC=C12 BEQRYHCXYAFPRU-UHFFFAOYSA-N 0.000 description 1
- CITBUWNJIQLRPB-UHFFFAOYSA-N 9-[(2-fluorophenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCC1=CC=CC=C1F CITBUWNJIQLRPB-UHFFFAOYSA-N 0.000 description 1
- FXEQIZHVYQIOKN-UHFFFAOYSA-N 9-[(2-fluorophenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound FC1=CC=CC=C1CNC1=C(C(=O)CCC2)C2=NC2=CC=CC=C12 FXEQIZHVYQIOKN-UHFFFAOYSA-N 0.000 description 1
- LLZPXWNSZOEXRM-UHFFFAOYSA-N 9-[(2-methoxyphenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound COC1=CC=CC=C1CNC1=C(C(O)CCC2)C2=NC2=CC=CC=C12 LLZPXWNSZOEXRM-UHFFFAOYSA-N 0.000 description 1
- RBRKTJWKILJWSY-UHFFFAOYSA-N 9-[(2-methoxyphenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound COC1=CC=CC=C1CNC1=C(C(=O)CCC2)C2=NC2=CC=CC=C12 RBRKTJWKILJWSY-UHFFFAOYSA-N 0.000 description 1
- ASZXFMFROJTYBD-UHFFFAOYSA-N 9-[(2-methylphenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound CC1=CC=CC=C1CNC1=C(C(O)CCC2)C2=NC2=CC=CC=C12 ASZXFMFROJTYBD-UHFFFAOYSA-N 0.000 description 1
- UINYYDDIQJCNLY-UHFFFAOYSA-N 9-[(2-methylphenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound CC1=CC=CC=C1CNC1=C(C(=O)CCC2)C2=NC2=CC=CC=C12 UINYYDDIQJCNLY-UHFFFAOYSA-N 0.000 description 1
- PAKRGUABUWIYQH-UHFFFAOYSA-N 9-[(3-chlorophenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCC1=CC=CC(Cl)=C1 PAKRGUABUWIYQH-UHFFFAOYSA-N 0.000 description 1
- JTDBOKMFQOOSGM-UHFFFAOYSA-N 9-[(3-chlorophenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound ClC1=CC=CC(CNC=2C3=CC=CC=C3N=C3CCCC(=O)C3=2)=C1 JTDBOKMFQOOSGM-UHFFFAOYSA-N 0.000 description 1
- OYECSEBZWOFEHH-UHFFFAOYSA-N 9-[(3-fluorophenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCC1=CC=CC(F)=C1 OYECSEBZWOFEHH-UHFFFAOYSA-N 0.000 description 1
- FGIQFWDLUQLRSY-UHFFFAOYSA-N 9-[(3-fluorophenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound FC1=CC=CC(CNC=2C3=CC=CC=C3N=C3CCCC(=O)C3=2)=C1 FGIQFWDLUQLRSY-UHFFFAOYSA-N 0.000 description 1
- DKUJACOBAKIJQF-UHFFFAOYSA-N 9-[(3-methoxyphenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound COC1=CC=CC(CNC=2C3=CC=CC=C3N=C3CCCC(O)C3=2)=C1 DKUJACOBAKIJQF-UHFFFAOYSA-N 0.000 description 1
- IHJHKGXTVXBZTN-UHFFFAOYSA-N 9-[(3-methoxyphenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound COC1=CC=CC(CNC=2C3=CC=CC=C3N=C3CCCC(=O)C3=2)=C1 IHJHKGXTVXBZTN-UHFFFAOYSA-N 0.000 description 1
- VQTIDCIBXATCPW-UHFFFAOYSA-N 9-[(3-methylphenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound CC1=CC=CC(CNC=2C3=CC=CC=C3N=C3CCCC(O)C3=2)=C1 VQTIDCIBXATCPW-UHFFFAOYSA-N 0.000 description 1
- KADMTFSMIOVGGS-UHFFFAOYSA-N 9-[(3-methylphenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound CC1=CC=CC(CNC=2C3=CC=CC=C3N=C3CCCC(=O)C3=2)=C1 KADMTFSMIOVGGS-UHFFFAOYSA-N 0.000 description 1
- HEKGBDCRHYILPL-UHFFFAOYSA-N 9-[(4-chlorophenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCC1=CC=C(Cl)C=C1 HEKGBDCRHYILPL-UHFFFAOYSA-N 0.000 description 1
- JUCJXAPYPXKKTH-UHFFFAOYSA-N 9-[(4-chlorophenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound C1=CC(Cl)=CC=C1CNC1=C(C(=O)CCC2)C2=NC2=CC=CC=C12 JUCJXAPYPXKKTH-UHFFFAOYSA-N 0.000 description 1
- APOMRWXYQSHYMK-UHFFFAOYSA-N 9-[(4-fluorophenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCC1=CC=C(F)C=C1 APOMRWXYQSHYMK-UHFFFAOYSA-N 0.000 description 1
- SPTZDSUPALKLJK-UHFFFAOYSA-N 9-[(4-fluorophenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound C1=CC(F)=CC=C1CNC1=C(C(=O)CCC2)C2=NC2=CC=CC=C12 SPTZDSUPALKLJK-UHFFFAOYSA-N 0.000 description 1
- GKQCJUSPLSEUKC-UHFFFAOYSA-N 9-[(4-methoxyphenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C1=CC(OC)=CC=C1CNC1=C(C(O)CCC2)C2=NC2=CC=CC=C12 GKQCJUSPLSEUKC-UHFFFAOYSA-N 0.000 description 1
- YCPZBHOZTZSCDZ-UHFFFAOYSA-N 9-[(4-methoxyphenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound C1=CC(OC)=CC=C1CNC1=C(C(=O)CCC2)C2=NC2=CC=CC=C12 YCPZBHOZTZSCDZ-UHFFFAOYSA-N 0.000 description 1
- IRPHKCJBSAUIII-UHFFFAOYSA-N 9-[(4-methylphenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C1=CC(C)=CC=C1CNC1=C(C(O)CCC2)C2=NC2=CC=CC=C12 IRPHKCJBSAUIII-UHFFFAOYSA-N 0.000 description 1
- AFOVBHWSLBYRMT-UHFFFAOYSA-N 9-[(4-methylphenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound C1=CC(C)=CC=C1CNC1=C(C(=O)CCC2)C2=NC2=CC=CC=C12 AFOVBHWSLBYRMT-UHFFFAOYSA-N 0.000 description 1
- KLRJPLZLGQUTQO-UHFFFAOYSA-N 9-[(4-phenylmethoxyphenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCC(C=C1)=CC=C1OCC1=CC=CC=C1 KLRJPLZLGQUTQO-UHFFFAOYSA-N 0.000 description 1
- ONAWRDUAMMKGLA-UHFFFAOYSA-N 9-[(4-phenylmethoxyphenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound C=12C(=O)CCCC2=NC2=CC=CC=C2C=1NCC(C=C1)=CC=C1OCC1=CC=CC=C1 ONAWRDUAMMKGLA-UHFFFAOYSA-N 0.000 description 1
- MSHWZHWOENOVTN-UHFFFAOYSA-N 9-[2-(dimethylamino)ethylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound C1=CC=C2C(NCCN(C)C)=C(C(=O)CCC3)C3=NC2=C1 MSHWZHWOENOVTN-UHFFFAOYSA-N 0.000 description 1
- QRJTYYJMOYGYCV-UHFFFAOYSA-N 9-[2-[bis(4-fluorophenyl)methoxy]ethylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCCOC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 QRJTYYJMOYGYCV-UHFFFAOYSA-N 0.000 description 1
- RMJNBGWBTQUGAS-UHFFFAOYSA-N 9-[4,4-bis(3-fluorophenyl)butylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCCCC(C=1C=C(F)C=CC=1)C1=CC=CC(F)=C1 RMJNBGWBTQUGAS-UHFFFAOYSA-N 0.000 description 1
- FJBDEUGVWSVISL-UHFFFAOYSA-N 9-[4,4-bis(3-fluorophenyl)butylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound FC1=CC=CC(C(CCCNC=2C3=CC=CC=C3N=C3CCCC(=O)C3=2)C=2C=C(F)C=CC=2)=C1 FJBDEUGVWSVISL-UHFFFAOYSA-N 0.000 description 1
- WFEGXUFMYIXSFD-UHFFFAOYSA-N 9-[4,4-bis(4-fluorophenyl)butylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 WFEGXUFMYIXSFD-UHFFFAOYSA-N 0.000 description 1
- VCSYBLCFSRDRJH-UHFFFAOYSA-N 9-[4,4-bis(4-fluorophenyl)butylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCNC1=C(C(=O)CCC2)C2=NC2=CC=CC=C12 VCSYBLCFSRDRJH-UHFFFAOYSA-N 0.000 description 1
- IJPJFSRSZPHFNX-UHFFFAOYSA-N 9-[[2-(trifluoromethyl)phenyl]methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCC1=CC=CC=C1C(F)(F)F IJPJFSRSZPHFNX-UHFFFAOYSA-N 0.000 description 1
- HQPLKPSUONVRCU-UHFFFAOYSA-N 9-[[2-(trifluoromethyl)phenyl]methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound FC(F)(F)C1=CC=CC=C1CNC1=C(C(=O)CCC2)C2=NC2=CC=CC=C12 HQPLKPSUONVRCU-UHFFFAOYSA-N 0.000 description 1
- UFRJCXVTCQWAIU-UHFFFAOYSA-N 9-[[3-(trifluoromethyl)phenyl]methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound FC(F)(F)C1=CC=CC(CNC=2C3=CC=CC=C3N=C3CCCC(=O)C3=2)=C1 UFRJCXVTCQWAIU-UHFFFAOYSA-N 0.000 description 1
- OWMWWMZMOLIDRD-UHFFFAOYSA-N 9-[[4-(trifluoromethyl)phenyl]methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCC1=CC=C(C(F)(F)F)C=C1 OWMWWMZMOLIDRD-UHFFFAOYSA-N 0.000 description 1
- FIFZQAUXSAQZLU-UHFFFAOYSA-N 9-[[4-(trifluoromethyl)phenyl]methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC1=C(C(=O)CCC2)C2=NC2=CC=CC=C12 FIFZQAUXSAQZLU-UHFFFAOYSA-N 0.000 description 1
- HLVVITIHAZBPKB-UHFFFAOYSA-N 9-amino-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C1=CC=C2C(N)=C(C(O)CCC3)C3=NC2=C1 HLVVITIHAZBPKB-UHFFFAOYSA-N 0.000 description 1
- BAXFTNIJRPIJEU-UHFFFAOYSA-N 9-amino-1-methyl-3,4-dihydro-2h-acridin-1-ol Chemical compound C1=CC=C2C(N)=C3C(C)(O)CCCC3=NC2=C1 BAXFTNIJRPIJEU-UHFFFAOYSA-N 0.000 description 1
- XUPOVMAQJOIDMZ-UHFFFAOYSA-N 9-amino-2,3,3a,4-tetrahydro-1h-cyclopenta[b]quinolin-1-ol Chemical compound N1C2=CC=CC=C2C(N)=C2C1CCC2O XUPOVMAQJOIDMZ-UHFFFAOYSA-N 0.000 description 1
- LKWKQKKNFMIICA-UHFFFAOYSA-N 9-amino-2,3-dihydrocyclopenta[b]quinolin-1-one Chemical compound C1=CC=C2C(N)=C(C(=O)CC3)C3=NC2=C1 LKWKQKKNFMIICA-UHFFFAOYSA-N 0.000 description 1
- XNJYRASUSQYMTL-UHFFFAOYSA-N 9-amino-2-methylidene-3,4-dihydroacridin-1-one Chemical compound C1=CC=C2C(N)=C(C(=O)C(=C)CC3)C3=NC2=C1 XNJYRASUSQYMTL-UHFFFAOYSA-N 0.000 description 1
- JUSJJSHTMCPMOX-UHFFFAOYSA-N 9-amino-3,4-dihydro-2h-acridin-1-one Chemical compound C1=CC=C2C(N)=C(C(=O)CCC3)C3=NC2=C1 JUSJJSHTMCPMOX-UHFFFAOYSA-N 0.000 description 1
- ZHFXMERFRYSFFB-UHFFFAOYSA-N 9-amino-6-(trifluoromethyl)-1,2,3,4-tetrahydroacridin-1-ol Chemical compound FC(F)(F)C1=CC=C2C(N)=C(C(O)CCC3)C3=NC2=C1 ZHFXMERFRYSFFB-UHFFFAOYSA-N 0.000 description 1
- RFEAONGCERLYIS-UHFFFAOYSA-N 9-amino-6-(trifluoromethyl)-3,4-dihydro-2h-acridin-1-one Chemical compound FC(F)(F)C1=CC=C2C(N)=C(C(=O)CCC3)C3=NC2=C1 RFEAONGCERLYIS-UHFFFAOYSA-N 0.000 description 1
- LHBQKFLAPXCANH-UHFFFAOYSA-N 9-amino-6-chloro-1,2,3,4-tetrahydroacridin-1-ol Chemical compound ClC1=CC=C2C(N)=C(C(O)CCC3)C3=NC2=C1 LHBQKFLAPXCANH-UHFFFAOYSA-N 0.000 description 1
- YTFJCNVHRDEWJN-UHFFFAOYSA-N 9-amino-6-chloro-3,4-dihydro-2h-acridin-1-one Chemical compound ClC1=CC=C2C(N)=C(C(=O)CCC3)C3=NC2=C1 YTFJCNVHRDEWJN-UHFFFAOYSA-N 0.000 description 1
- GHPCZOLZFWUXCH-UHFFFAOYSA-N 9-amino-6-fluoro-1,2,3,4-tetrahydroacridin-1-ol Chemical compound FC1=CC=C2C(N)=C(C(O)CCC3)C3=NC2=C1 GHPCZOLZFWUXCH-UHFFFAOYSA-N 0.000 description 1
- BQODEXMWLQQVQQ-UHFFFAOYSA-N 9-amino-6-fluoro-3,4-dihydro-2h-acridin-1-one Chemical compound FC1=CC=C2C(N)=C(C(=O)CCC3)C3=NC2=C1 BQODEXMWLQQVQQ-UHFFFAOYSA-N 0.000 description 1
- OALAJFHZGANODE-UHFFFAOYSA-N 9-amino-6-methoxy-1,2,3,4-tetrahydroacridin-1-ol Chemical compound OC1CCCC2=NC3=CC(OC)=CC=C3C(N)=C21 OALAJFHZGANODE-UHFFFAOYSA-N 0.000 description 1
- WMLMRDSLHWHTTP-UHFFFAOYSA-N 9-amino-6-methoxy-3,4-dihydro-2h-acridin-1-one Chemical compound O=C1CCCC2=NC3=CC(OC)=CC=C3C(N)=C21 WMLMRDSLHWHTTP-UHFFFAOYSA-N 0.000 description 1
- UVGIDXFDFPOSEE-UHFFFAOYSA-N 9-amino-6-methyl-3,4-dihydro-2h-acridin-1-one Chemical compound O=C1CCCC2=NC3=CC(C)=CC=C3C(N)=C21 UVGIDXFDFPOSEE-UHFFFAOYSA-N 0.000 description 1
- SJMIUHDBFGTYAA-UHFFFAOYSA-N 9-amino-7-chloro-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C1=C(Cl)C=C2C(N)=C(C(O)CCC3)C3=NC2=C1 SJMIUHDBFGTYAA-UHFFFAOYSA-N 0.000 description 1
- QMJVYXYAJRUSOK-UHFFFAOYSA-N 9-amino-7-chloro-3,4-dihydro-2h-acridin-1-one Chemical compound C1=C(Cl)C=C2C(N)=C(C(=O)CCC3)C3=NC2=C1 QMJVYXYAJRUSOK-UHFFFAOYSA-N 0.000 description 1
- NGGNNYCJIOMJBD-UHFFFAOYSA-N 9-amino-7-nitro-3,4-dihydro-2h-acridin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(N)=C(C(=O)CCC3)C3=NC2=C1 NGGNNYCJIOMJBD-UHFFFAOYSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 102000035101 Aspartic proteases Human genes 0.000 description 1
- 108091005502 Aspartic proteases Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- MYTVVMGUDBRCDJ-UHFFFAOYSA-N Bufencarb Chemical compound CCCC(C)C1=CC=CC(OC(=O)NC)=C1.CCC(CC)C1=CC=CC(OC(=O)NC)=C1 MYTVVMGUDBRCDJ-UHFFFAOYSA-N 0.000 description 1
- 244000045232 Canavalia ensiformis Species 0.000 description 1
- TWFZGCMQGLPBSX-UHFFFAOYSA-N Carbendazim Natural products C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 1
- 239000005490 Carbetamide Substances 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102100036806 Carboxylesterase 5A Human genes 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 1
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 1
- 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 description 1
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 1
- 101100135859 Dictyostelium discoideum regA gene Proteins 0.000 description 1
- 239000005947 Dimethoate Substances 0.000 description 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 1
- 101001117089 Drosophila melanogaster Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1 Proteins 0.000 description 1
- 108091065810 E family Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- VWLHWLSRQJQWRG-UHFFFAOYSA-O Edrophonum Chemical compound CC[N+](C)(C)C1=CC=CC(O)=C1 VWLHWLSRQJQWRG-UHFFFAOYSA-O 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- IJWCGVPEDDQUDE-UHFFFAOYSA-N Elastatinal Natural products O=CC(C)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)NC(CC(C)C)C(O)=O)C1CCN=C(N)N1 IJWCGVPEDDQUDE-UHFFFAOYSA-N 0.000 description 1
- 229940124143 Endopeptidase inhibitor Drugs 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000001134 F-test Methods 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 239000005948 Formetanate Substances 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 101150021955 GIP1 gene Proteins 0.000 description 1
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 1
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- FRJIAZKQGSCKPQ-FSPLSTOPSA-N His-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1 FRJIAZKQGSCKPQ-FSPLSTOPSA-N 0.000 description 1
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 1
- 241001090156 Huperzia serrata Species 0.000 description 1
- 102100032999 Integrin beta-3 Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- LCPYQJIKPJDLLB-UWVGGRQHSA-N Leu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C LCPYQJIKPJDLLB-UWVGGRQHSA-N 0.000 description 1
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 1
- JJPMUZRSJKMFRK-OQMKEHIESA-N Lycodine Chemical class N1CCC[C@@H]2[C@H]3C[C@@H](C)C[C@]21C1=CC=CN=C1C3 JJPMUZRSJKMFRK-OQMKEHIESA-N 0.000 description 1
- 241000195947 Lycopodium Species 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 239000005949 Malathion Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 239000005951 Methiocarb Substances 0.000 description 1
- 239000005916 Methomyl Substances 0.000 description 1
- RJWLAIMXRBDUMH-ULQDDVLXSA-N N-Acetylleucyl-leucyl-methioninal Chemical compound CSCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(C)=O RJWLAIMXRBDUMH-ULQDDVLXSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- BEKQPDFPPJFVJP-AHSQCEKMSA-N Onchidal Chemical compound CC(=O)O\C=C\C(\C=O)=C/CC1C(=C)CCCC1(C)C BEKQPDFPPJFVJP-AHSQCEKMSA-N 0.000 description 1
- JLVLVOITZSLHPU-UHFFFAOYSA-N Onchidal Natural products CC(=O)OC(=CC(=C/CC1C(=C)CCCC1(C)C)C=O)C JLVLVOITZSLHPU-UHFFFAOYSA-N 0.000 description 1
- 239000005950 Oxamyl Substances 0.000 description 1
- 101710137390 P-selectin glycoprotein ligand 1 Proteins 0.000 description 1
- 108010054395 P-selectin ligand protein Proteins 0.000 description 1
- 101150098694 PDE5A gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 235000010617 Phaseolus lunatus Nutrition 0.000 description 1
- 239000005594 Phenmedipham Substances 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 239000005923 Pirimicarb Substances 0.000 description 1
- 101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 description 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 1
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 1
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 239000004696 Poly ether ether ketone Substances 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000005821 Propamocarb Substances 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 102000007466 Purinergic P2 Receptors Human genes 0.000 description 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 description 1
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 description 1
- ISRUGXGCCGIOQO-UHFFFAOYSA-N Rhoden Chemical compound CNC(=O)OC1=CC=CC=C1OC(C)C ISRUGXGCCGIOQO-UHFFFAOYSA-N 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 101100135860 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDE2 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101710097834 Thiol protease Proteins 0.000 description 1
- 108010036928 Thiorphan Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- NHXZRXLFOBFMDM-AVGNSLFASA-N Val-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C NHXZRXLFOBFMDM-AVGNSLFASA-N 0.000 description 1
- AMRQXHFXNZFDCH-SECBINFHSA-N [(2r)-1-(ethylamino)-1-oxopropan-2-yl] n-phenylcarbamate Chemical compound CCNC(=O)[C@@H](C)OC(=O)NC1=CC=CC=C1 AMRQXHFXNZFDCH-SECBINFHSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- PJVJTCIRVMBVIA-JTQLQIEISA-N [dimethylamino(ethoxy)phosphoryl]formonitrile Chemical compound CCO[P@@](=O)(C#N)N(C)C PJVJTCIRVMBVIA-JTQLQIEISA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- QGLZXHRNAYXIBU-WEVVVXLNSA-N aldicarb Chemical compound CNC(=O)O\N=C\C(C)(C)SC QGLZXHRNAYXIBU-WEVVVXLNSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 1
- 229960001667 alogliptin Drugs 0.000 description 1
- 229960000451 ambenonium Drugs 0.000 description 1
- OMHBPUNFVFNHJK-UHFFFAOYSA-P ambenonium Chemical compound C=1C=CC=C(Cl)C=1C[N+](CC)(CC)CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl OMHBPUNFVFNHJK-UHFFFAOYSA-P 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000000636 anti-proteolytic effect Effects 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- XEGGRYVFLWGFHI-UHFFFAOYSA-N bendiocarb Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)O2 XEGGRYVFLWGFHI-UHFFFAOYSA-N 0.000 description 1
- JUPQTSLXMOCDHR-UHFFFAOYSA-N benzene-1,4-diol;bis(4-fluorophenyl)methanone Chemical compound OC1=CC=C(O)C=C1.C1=CC(F)=CC=C1C(=O)C1=CC=C(F)C=C1 JUPQTSLXMOCDHR-UHFFFAOYSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 1
- 108010053420 calpain inhibitor 2 Proteins 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 229960005286 carbaryl Drugs 0.000 description 1
- CVXBEEMKQHEXEN-UHFFFAOYSA-N carbaryl Chemical compound C1=CC=C2C(OC(=O)NC)=CC=CC2=C1 CVXBEEMKQHEXEN-UHFFFAOYSA-N 0.000 description 1
- 239000006013 carbendazim Substances 0.000 description 1
- JNPZQRQPIHJYNM-UHFFFAOYSA-N carbendazim Chemical compound C1=C[CH]C2=NC(NC(=O)OC)=NC2=C1 JNPZQRQPIHJYNM-UHFFFAOYSA-N 0.000 description 1
- DUEPRVBVGDRKAG-UHFFFAOYSA-N carbofuran Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)C2 DUEPRVBVGDRKAG-UHFFFAOYSA-N 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- CWJSHJJYOPWUGX-UHFFFAOYSA-N chlorpropham Chemical compound CC(C)OC(=O)NC1=CC=CC(Cl)=C1 CWJSHJJYOPWUGX-UHFFFAOYSA-N 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 108010086192 chymostatin Proteins 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 101150005346 coaBC gene Proteins 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical class C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- SNTRKUOVAPUGAY-UHFFFAOYSA-N cyclosarin Chemical compound CP(F)(=O)OC1CCCCC1 SNTRKUOVAPUGAY-UHFFFAOYSA-N 0.000 description 1
- 108050004038 cystatin Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- RWZVPVOZTJJMNU-UHFFFAOYSA-N demarcarium Chemical compound C=1C=CC([N+](C)(C)C)=CC=1OC(=O)N(C)CCCCCCCCCCN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 RWZVPVOZTJJMNU-UHFFFAOYSA-N 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 1
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical class [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 229960002819 diprophylline Drugs 0.000 description 1
- 108010054812 diprotin A Proteins 0.000 description 1
- 108010054813 diprotin B Proteins 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 229960002017 echothiophate Drugs 0.000 description 1
- BJOLKYGKSZKIGU-UHFFFAOYSA-N ecothiopate Chemical compound CCOP(=O)(OCC)SCC[N+](C)(C)C BJOLKYGKSZKIGU-UHFFFAOYSA-N 0.000 description 1
- 229960003748 edrophonium Drugs 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 108010039262 elastatinal Proteins 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- HEZNVIYQEUHLNI-UHFFFAOYSA-N ethiofencarb Chemical compound CCSCC1=CC=CC=C1OC(=O)NC HEZNVIYQEUHLNI-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 150000004665 fatty acids Chemical group 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- RMFNNCGOSPBBAD-MDWZMJQESA-N formetanate Chemical compound CNC(=O)OC1=CC=CC(\N=C\N(C)C)=C1 RMFNNCGOSPBBAD-MDWZMJQESA-N 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000004023 fresh frozen plasma Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical group C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 108010040030 histidinoalanine Proteins 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- QTPHSDHUHXUYFE-UHFFFAOYSA-N huprine x Chemical compound N1=C2C=C(Cl)C=CC2=C(N)C2=C1CC1C=C(CC)CC2C1 QTPHSDHUHXUYFE-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 108010091798 leucylleucine Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960002397 linagliptin Drugs 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 235000015073 liquid stocks Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229960000453 malathion Drugs 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- YFBPRJGDJKVWAH-UHFFFAOYSA-N methiocarb Chemical compound CNC(=O)OC1=CC(C)=C(SC)C(C)=C1 YFBPRJGDJKVWAH-UHFFFAOYSA-N 0.000 description 1
- UHXUZOCRWCRNSJ-QPJJXVBHSA-N methomyl Chemical compound CNC(=O)O\N=C(/C)SC UHXUZOCRWCRNSJ-QPJJXVBHSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960001952 metrifonate Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- YXYXCYQIHJLUHU-UHFFFAOYSA-N n'-(6,8-dichloro-1,2,3,4-tetrahydroacridin-9-yl)-n-(1,2,3,4-tetrahydroacridin-9-yl)heptane-1,7-diamine Chemical compound C1CCCC2=NC3=CC(Cl)=CC(Cl)=C3C(NCCCCCCCNC=3C4=CC=CC=C4N=C4CCCCC4=3)=C21 YXYXCYQIHJLUHU-UHFFFAOYSA-N 0.000 description 1
- AXLKXPGGRMASKW-UHFFFAOYSA-N n,n'-bis(6,8-dichloro-1,2,3,4-tetrahydroacridin-9-yl)heptane-1,7-diamine Chemical compound C1CCCC2=NC3=CC(Cl)=CC(Cl)=C3C(NCCCCCCCNC=3C4=C(Cl)C=C(Cl)C=C4N=C4CCCCC4=3)=C21 AXLKXPGGRMASKW-UHFFFAOYSA-N 0.000 description 1
- YFCUZWYIPBUQBD-ZOWNYOTGSA-N n-[(3s)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide;hydron;chloride Chemical compound Cl.CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 YFCUZWYIPBUQBD-ZOWNYOTGSA-N 0.000 description 1
- BLSWTOZZEVRLDD-UHFFFAOYSA-N n-[7-[(6,8-dichloro-1,2,3,4-tetrahydroacridin-9-yl)sulfanyl]heptyl]-1,2,3,4-tetrahydroacridin-9-amine Chemical compound C1CCCC2=NC3=CC(Cl)=CC(Cl)=C3C(SCCCCCCCNC=3C4=CC=CC=C4N=C4CCCCC4=3)=C21 BLSWTOZZEVRLDD-UHFFFAOYSA-N 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- IYPDMKXIHUEQCR-UHFFFAOYSA-N non-6-ene-1,3-diamine Chemical compound C(CC(CCC=CCC)N)N IYPDMKXIHUEQCR-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 108010000416 ovomacroglobulin Proteins 0.000 description 1
- KZAUOCCYDRDERY-UHFFFAOYSA-N oxamyl Chemical compound CNC(=O)ON=C(SC)C(=O)N(C)C KZAUOCCYDRDERY-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940100256 oxtriphylline Drugs 0.000 description 1
- RLANKEDHRWMNRO-UHFFFAOYSA-M oxtriphylline Chemical compound C[N+](C)(C)CCO.O=C1N(C)C(=O)N(C)C2=C1[N-]C=N2 RLANKEDHRWMNRO-UHFFFAOYSA-M 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- IDOWTHOLJBTAFI-UHFFFAOYSA-N phenmedipham Chemical compound COC(=O)NC1=CC=CC(OC(=O)NC=2C=C(C)C=CC=2)=C1 IDOWTHOLJBTAFI-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- YFGYUFNIOHWBOB-UHFFFAOYSA-N pirimicarb Chemical compound CN(C)C(=O)OC1=NC(N(C)C)=NC(C)=C1C YFGYUFNIOHWBOB-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920002530 polyetherether ketone Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 150000007519 polyprotic acids Chemical class 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- WZZLDXDUQPOXNW-UHFFFAOYSA-N propamocarb Chemical compound CCCOC(=O)NCCCN(C)C WZZLDXDUQPOXNW-UHFFFAOYSA-N 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- VXPLXMJHHKHSOA-UHFFFAOYSA-N propham Chemical compound CC(C)OC(=O)NC1=CC=CC=C1 VXPLXMJHHKHSOA-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229960002290 pyridostigmine Drugs 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012858 resilient material Substances 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000008275 solid aerosol Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- LJJKNPQAGWVLDQ-SNVBAGLBSA-N thiorphan Chemical compound OC(=O)CNC(=O)[C@@H](CS)CC1=CC=CC=C1 LJJKNPQAGWVLDQ-SNVBAGLBSA-N 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229920006352 transparent thermoplastic Polymers 0.000 description 1
- 229960005032 treprostinil Drugs 0.000 description 1
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 description 1
- NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150015—Source of blood
- A61B5/15003—Source of blood for venous or arterial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
- A61B5/150274—Manufacture or production processes or steps for blood sampling devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150351—Caps, stoppers or lids for sealing or closing a blood collection vessel or container, e.g. a test-tube or syringe barrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
- A61B5/150381—Design of piercing elements
- A61B5/150389—Hollow piercing elements, e.g. canulas, needles, for piercing the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
- A61B5/150381—Design of piercing elements
- A61B5/150473—Double-ended needles, e.g. used with pre-evacuated sampling tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150755—Blood sample preparation for further analysis, e.g. by separating blood components or by mixing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/153—Devices specially adapted for taking samples of venous or arterial blood, e.g. with syringes
- A61B5/154—Devices using pre-evacuated means
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5021—Test tubes specially adapted for centrifugation purposes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/491—Blood by separating the blood components
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/16—Reagents, handling or storing thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/04—Closures and closing means
- B01L2300/041—Connecting closures to device or container
- B01L2300/044—Connecting closures to device or container pierceable, e.g. films, membranes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Surgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Manufacturing & Machinery (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Ecology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Biochemistry (AREA)
- Environmental Sciences (AREA)
- Immunology (AREA)
- Clinical Laboratory Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Physiology (AREA)
- Sampling And Sample Adjustment (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261594152P | 2012-02-02 | 2012-02-02 | |
| US61/594,152 | 2012-02-02 | ||
| PCT/US2013/024416 WO2013116702A1 (en) | 2012-02-02 | 2013-02-01 | Sample collection devices with blood stabilizing agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2862544A1 true CA2862544A1 (en) | 2013-08-08 |
Family
ID=48905892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2862544A Abandoned CA2862544A1 (en) | 2012-02-02 | 2013-02-01 | Sample collection devices with blood stabilizing agents |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20130209985A1 (en:Method) |
| EP (1) | EP2809289A4 (en:Method) |
| JP (1) | JP2015506482A (en:Method) |
| CN (1) | CN104244902A (en:Method) |
| AU (1) | AU2013214866A1 (en:Method) |
| BR (1) | BR112014018970A8 (en:Method) |
| CA (1) | CA2862544A1 (en:Method) |
| IN (1) | IN2014DN06981A (en:Method) |
| MX (1) | MX2014009256A (en:Method) |
| WO (1) | WO2013116702A1 (en:Method) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2684130T3 (es) | 2009-04-09 | 2018-10-01 | Entegrion, Inc. | Productos de la sangre secados por aspersión y métodos para elaborar los mismos |
| US20110142885A1 (en) | 2009-09-16 | 2011-06-16 | Velico Medical, Inc. | Spray-dried human plasma |
| US20140083628A1 (en) | 2012-09-27 | 2014-03-27 | Velico Medical, Inc. | Spray drier assembly for automated spray drying |
| JP6382323B2 (ja) * | 2014-01-30 | 2018-08-29 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 室温での全血の安定化 |
| US9561184B2 (en) * | 2014-09-19 | 2017-02-07 | Velico Medical, Inc. | Methods and systems for multi-stage drying of plasma |
| US11168351B2 (en) | 2015-03-05 | 2021-11-09 | Streck, Inc. | Stabilization of nucleic acids in urine |
| EP4574040A3 (en) * | 2015-08-13 | 2025-08-27 | Takeda Pharmaceutical Company Limited | Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation |
| US20170145475A1 (en) | 2015-11-20 | 2017-05-25 | Streck, Inc. | Single spin process for blood plasma separation and plasma composition including preservative |
| EP3847965A1 (en) | 2015-12-11 | 2021-07-14 | Babson Diagnostics, Inc. | Specimen container and method for separating serum or plasma from whole blood |
| CN105372109A (zh) * | 2015-12-15 | 2016-03-02 | 苏州药明康德新药开发股份有限公司 | 添加稳定剂的生物基质的制备方法 |
| EP4656715A2 (en) | 2016-07-29 | 2025-12-03 | Streck LLC | Suspension composition for hematology analysis control |
| JP7101174B2 (ja) | 2016-11-14 | 2022-07-14 | バブソン ダイアグノスティックス インコーポレイテッド | サンプル調製装置 |
| CN111278476B (zh) | 2017-09-22 | 2023-01-17 | 贝克顿·迪金森公司 | 用作导管封管液的4％柠檬酸三钠溶液 |
| WO2019079743A1 (en) | 2017-10-19 | 2019-04-25 | Streck, Inc. | COMPOSITIONS FOR HEMOLYSIS AND REGULATION OF COAGULATION AND STABILIZATION OF EXTRACELLULAR VESICLES |
| EP4439040A3 (en) * | 2017-11-15 | 2025-01-01 | Radiometer Medical ApS | Heparin-based blood sampler without platelet activation |
| CN108311121B (zh) * | 2018-01-25 | 2021-05-14 | 健帆生物科技集团股份有限公司 | 一种血液灌流用吸附树脂及其制备方法和灌流器 |
| WO2019210195A1 (en) * | 2018-04-27 | 2019-10-31 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Integrated device for self-collecting and automated pre-processing of biological fluids |
| JP7334468B2 (ja) * | 2018-05-29 | 2023-08-29 | 東ソー株式会社 | 血液試料保存剤 |
| JP7036670B2 (ja) * | 2018-05-31 | 2022-03-15 | アークレイ株式会社 | 血液中の稀少細胞検査、該検査ための血液処理方法及び採血管 |
| WO2020185393A1 (en) * | 2019-03-11 | 2020-09-17 | Siemens Healthcare Diagnostics Inc. | Syringe apparatus and methods |
| KR102784001B1 (ko) * | 2019-05-14 | 2025-03-18 | 라디오미터 메디컬 에이피에스 | 혈액 가스 또는 대사 파라미터를 결정하기 위한 방법 |
| JP7402727B2 (ja) * | 2020-03-26 | 2023-12-21 | テルモ株式会社 | リン脂質含有物質安定化剤およびそれを含む体液検査キット |
| CN111521455A (zh) * | 2020-04-27 | 2020-08-11 | 中国科学院西北生态环境资源研究院 | 一种取样注射器的夹持单元及夹持方法 |
| CN112063513A (zh) * | 2020-09-21 | 2020-12-11 | 湖南洪江嵩云禽业有限公司 | 新型冰鲜禽肉储运新鲜度安全示警卡 |
| EP4253953A4 (en) * | 2020-11-25 | 2024-09-25 | Provigate Inc. | BLOOD PLASMA OR SERUM SEPARATION AND STORAGE MEDIUM, PRODUCTION METHOD THEREOF, DEVICE, KIT AND METHOD FOR MEASURING GLYCOSYLATED PROTEIN |
| WO2022136545A1 (en) * | 2020-12-22 | 2022-06-30 | Radiometer Medical Aps | Blood sampler containing anti-platelet agent and water-soluble matrix material |
| US12050052B1 (en) | 2021-08-06 | 2024-07-30 | Babson Diagnostics, Inc. | Refrigerated carrier device for biological samples |
| CN118317736A (zh) * | 2021-11-11 | 2024-07-09 | Prp技术公司 | 样本采集设备 |
| CN118284808A (zh) * | 2022-03-25 | 2024-07-02 | 积水医疗株式会社 | 循环肿瘤细胞分离试剂盒、循环肿瘤细胞分离容器及循环肿瘤细胞的分离方法 |
| EP4505185A1 (en) | 2022-04-06 | 2025-02-12 | Babson Diagnostics, Inc. | Automated centrifuge loader |
| US11975274B2 (en) | 2022-09-15 | 2024-05-07 | Velico Medical, Inc. | Blood plasma product |
| US12246266B2 (en) | 2022-09-15 | 2025-03-11 | Velico Medical, Inc. | Disposable for a spray drying system |
| WO2024059770A1 (en) | 2022-09-15 | 2024-03-21 | Velico Medical, Inc. | Rapid spray drying system |
| US11998861B2 (en) | 2022-09-15 | 2024-06-04 | Velico Medical, Inc. | Usability of a disposable for a spray drying plasma system |
| US12083447B2 (en) | 2022-09-15 | 2024-09-10 | Velico Medical, Inc. | Alignment of a disposable for a spray drying plasma system |
| US11841189B1 (en) | 2022-09-15 | 2023-12-12 | Velico Medical, Inc. | Disposable for a spray drying system |
| US12246093B2 (en) | 2022-09-15 | 2025-03-11 | Velico Medical, Inc. | Methods for making spray dried plasma |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4104606C1 (en:Method) * | 1991-02-12 | 1992-10-15 | Schering Ag Berlin Und Bergkamen, 1000 Berlin, De | |
| FR2729823B1 (fr) * | 1995-01-31 | 2001-08-31 | Samama Meyer | Conservation de prelevements de sang, en particulier chez les malades traites par l'heparine |
| US6139878A (en) * | 1998-04-27 | 2000-10-31 | Aventis Behring, Llc | Method for preparing a diafiltered stabilized blood product |
| AU2001292894A1 (en) * | 2000-09-20 | 2002-04-02 | Surromed, Inc. | Method for monitoring resting and activated platelets in unfixed blood samples |
| KR100451485B1 (ko) * | 2002-03-28 | 2004-10-06 | 주식회사종근당 | 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물 |
| CN102353569A (zh) * | 2002-05-13 | 2012-02-15 | 贝克顿·迪金森公司 | 蛋白酶抑制剂样品采集系统 |
| ES2347564T3 (es) * | 2003-08-05 | 2010-11-02 | Becton, Dickinson And Company | Dispositivo y metodos para la recogida de una muestra de fluido biologico y el tratmaiento de componentes seleccionados. |
| US20090123907A1 (en) * | 2004-07-22 | 2009-05-14 | Shanbrom Technologies, Llc | Lysine citrate for plasma protein and donor protection |
| US7700046B2 (en) * | 2004-09-14 | 2010-04-20 | Goldenberg Alec S | Controlled additive/reactant delivery system |
| DE102006020386A1 (de) * | 2006-04-28 | 2007-10-31 | Dade Behring Marburg Gmbh | Verfahren zur Bestimmung der Thrombozytenfunktion unter Flussbedingungen |
| DE102006045550A1 (de) * | 2006-09-25 | 2008-04-03 | Dade Behring Marburg Gmbh | Verfahren zur Herstellung von agglutionationsfähigen Thrombozytenfragmenten und deren Verwendung |
-
2013
- 2013-02-01 CA CA2862544A patent/CA2862544A1/en not_active Abandoned
- 2013-02-01 WO PCT/US2013/024416 patent/WO2013116702A1/en not_active Ceased
- 2013-02-01 CN CN201380016577.5A patent/CN104244902A/zh active Pending
- 2013-02-01 AU AU2013214866A patent/AU2013214866A1/en not_active Abandoned
- 2013-02-01 BR BR112014018970A patent/BR112014018970A8/pt not_active IP Right Cessation
- 2013-02-01 JP JP2014555777A patent/JP2015506482A/ja active Pending
- 2013-02-01 EP EP13743592.1A patent/EP2809289A4/en not_active Withdrawn
- 2013-02-01 US US13/757,080 patent/US20130209985A1/en not_active Abandoned
- 2013-02-01 IN IN6981DEN2014 patent/IN2014DN06981A/en unknown
- 2013-02-01 MX MX2014009256A patent/MX2014009256A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015506482A (ja) | 2015-03-02 |
| IN2014DN06981A (en:Method) | 2015-04-10 |
| MX2014009256A (es) | 2014-09-25 |
| AU2013214866A1 (en) | 2014-09-04 |
| CN104244902A (zh) | 2014-12-24 |
| BR112014018970A8 (pt) | 2017-07-11 |
| EP2809289A1 (en) | 2014-12-10 |
| BR112014018970A2 (en:Method) | 2017-06-20 |
| WO2013116702A1 (en) | 2013-08-08 |
| EP2809289A4 (en) | 2015-12-30 |
| US20130209985A1 (en) | 2013-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20130209985A1 (en) | Sample collection devices with blood stabilizing agents | |
| JP5844826B2 (ja) | リゾホスホリパーゼ阻害剤を含む採血デバイス | |
| JP5937612B2 (ja) | 血液安定剤を含む採血用デバイス | |
| JP4496407B2 (ja) | プロテアーゼ阻害剤試料採取システム | |
| AU2011202059B2 (en) | Phosphatase inhibitor sample collection system | |
| EP2940119B1 (en) | Buffy coat extraction kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140724 |
|
| FZDE | Discontinued |
Effective date: 20180201 |